Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Metastasis and Neurobiology Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CRMP1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CRMP1 Recombinant Protein (WT / Phospho-mimetic Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View CRMP1 Products |
| Gene Delivery | CRMP1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and migration assays. |
View CRMP1 Products |
| Benchmark Ab | Anti-CRMP1 Antibody Recombinant positive control for Western Blot and IHC. |
View CRMP1 Products |
| Validator | CRMP1 siRNA Set For knockdown verification in tumor invasion models. |
View CRMP1 Products |
| Related Target A | CRMP2 (DPYSL2) Highly homologous family member; essential for selectivity profiling. |
View CRMP2 Products |
| Related Target B | SEMA3A Upstream ligand initiating the CRMP1-mediated growth cone collapse pathway. |
View SEMA3A Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| CRMP Family Subtype Cross-reactivity | CRMP1 and CRMP2 ortholog proteins available with >95% purity for off-target counter-screening. |
| Intracellular Phosphorylation State Mimicry | Specific phosphorylation-site mutant proteins (e.g., Thr509/Thr514) verified by mass spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and high-affinity validation antibodies included. |
| False Positives in Migration Assays | Validated siRNA sets included for target-specific knockdown verification. |
Live CRMP1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic development surrounding CRMP1 (Collapsing Response Mediator Protein 1) is expanding beyond its classical role in axon guidance into oncology. As a cytosolic protein that regulates microtubule dynamics and actin organization, CRMP1 primarily acts as a metastasis suppressor in multiple solid tumors, including non-small cell lung cancer (NSCLC) and breast cancer. Conversely, its aberrant phosphorylation is linked to neurodegenerative disorders and neuropathic pain.
The next wave of R&D focuses on small molecules modulating CRMP1 phosphorylation states (preventing Cdk5/GSK3β-mediated inactivation) and gene therapy/mRNA platforms aimed at restoring CRMP1 expression in metastatic cancers. Developing high-fidelity screening assays that distinguish CRMP1 from its close homolog CRMP2 is critical for safety and efficacy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Kinase/PP2A Modulators) | Academic Consortia, Biotech Startups | Neuropathic Pain, Alzheimer's Disease | Selectivity Assay (Need CRMP1 vs CRMP2 WT & Mutant Proteins) |
| Gene Therapy / mRNA | Oncology Therapeutics Developers | Metastatic NSCLC, Breast Cancer | Expression validation (Need Lentivirus for Stable Line Construction) |
| Peptide Inhibitors | Neurology-focused Biopharma | Spinal Cord Injury, Neurodegeneration | Protein-Protein Interaction (PPI) assays (Need High-Purity Recombinant CRMP1) |